Bouabdallah R, Xerri L, Bardou V J, Stoppa A M, Blaise D, Sainty D, Maraninchi D, Gastaut J A
Department of Hematology, Institut J. Paoli-I. Calmettes, Marseille, France.
Ann Oncol. 1998 Jun;9(6):619-25. doi: 10.1023/a:1008202808144.
To describe the outcome of an unselected large series of patients with lymphoblastic lymphoma (LBL) treated in a single institution.
Sixty-two patients were treated between 1980 and 1992. Induction chemotherapy (CT) to achieve complete response (CR) was: French Multicenter Acute Lymphoblastic Leukemia (ALL) protocols (38), non-Hodgkin's Lymphoma (NHL) protocols (20). Thirty patients underwent transplant after achieving CR (allogeneic 12; autologous 18).
Forty-six patients (74%) achieved CR and 16 (26%) failed to respond. The patients who received an ALL induction had an 89% CR rate, while the CR rate was 52% in patients who received a NHL-like regimen. With a median follow-up of 93 months (range 36-187), the actuarial overall survival (OS) rate for all patients is 49% at five years and 41% at 10 years, and the actuarial event-free survival (EFS) rate is 45% and 37%. OS and EFS in the grafted population are, respectively, 60% and 56% at five years. Our results also show a trend toward a longer OS in allografted group.
ALL induction therapy is more effective than the NHL-like regimen for augmenting the CR rate. Autologous or allogeneic transplantation should be considered as consolidation therapy in high-risk group patients.
